Centre launches PLI for 11 pharma goods

• The list includes Neomycin, Gentamycin, Erythromycin, Streptomycin, Tetracycline, Ciprofloxacin, and Diclofenac Sodium.

• The deadline for applications is June 14.

• Conditions include allocation based on available capacities, incentive ceiling, and limit of incentive up to production tenure.

• Companies that withdrew or cancelled their approval earlier are not eligible.

• The Pharmaceuticals Export Promotion Council of India encourages its members to benefit from the decision.

• The scheme is part of India’s emphasis on domestic manufacturing of key starting materials, drug intermediates, and active pharmaceutical ingredients.

• The scheme covers 41 products and has a financial outlay of ₹6,940 crore.